Volume 28, Number 3—March 2022
Dispatch
Disseminated Histoplasmosis in Persons with HIV/AIDS, Southern Brazil, 2010–2019
Rossana Patricia Basso, Vanice Rodrigues Poester, Jéssica Louise Benelli, David A. Stevens, and Melissa Orzechowski Xavier
Table 1
Clinical-epidemiologic data of 31 disseminated histoplasmosis cases diagnosed in persons living with HIV/AIDS, University Hospital Dr. Miguel Riet Corrêa Jr., Rio Grande, Brazil, 2010–2019
| Variable | Frequency, % (no./total no. participants) |
|---|---|
| M | 74 (21/31) |
| F |
26 (8/31) |
| Signs and symptoms | |
| Weight loss | 100 (31/31) |
| Fever (>37.8°C) | 100 (31/31) |
| Respiratory: cough and/or dyspnea | 100 (31/31) |
| Cutaneous: papular and/or ulcerated | 52 (16/31) |
| Neurologic: disorientation, focal deficit, paresthesia, confusion, headache and/or hemiplegia | 52 (16/31) |
| Digestive: abdominal distension and pain, diarrhea and/or nausea | 81 (25/31) |
| Hepatomegaly | 55 (17/31) |
| Splenomegaly | 81 (25/31) |
| Generalized lymph node enlargement |
35 (11/31) |
| Image exams | |
| Interstitial lung pattern | 55 (17/31) |
| Reticulonodular lung pattern | 32 (10/31) |
| Pulmonary nodules | 6 (2/31) |
| Mediastinal lymphadenopathy |
26 (8/31) |
| Blood assays | |
| Anemia | 100 (31/31) |
| Inflammatory marker* | 100 (31/31) |
| Liver damage marker† | 84 (26/31) |
| Tissue injury marker‡ | 87 (27/31) |
| Thrombocytopenia |
74 (23/31) |
| HIV assays | |
| CD4+ lymphocytes ≤100/mm3 | 71 (22/31) |
| CD4+ lymphocytes ≤50/mm3 | 48 (15/31) |
| HIV Viral load ≥50,000 copies |
90 (26/29) |
| First choice antifungal treatment | |
| None | 3 (1/31) |
| Amphotericin B deoxycholate | 81 (25/31) |
| Itraconazole |
16 (5/31) |
| Outcome after 12 months | |
| Alive | 65 (20/31) |
| Dead | 35 (11/31) |
*C-reactive protein increased. †Alkaline phosphatase increased. ‡Lactate dehydrogenase increased.
Page created: January 27, 2022
Page updated: February 21, 2022
Page reviewed: February 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.